The Subclinical Window for Cardioprotection in Duchenne Muscular Dystrophy: A Systematic Review and Meta-analysis [0.03%]
杜氏肌营养不良心脏保护的亚临床窗口：系统性回顾和meta分析
Feras Shatarat,Amer A Alomari,Osama Bdarnh et al.
Feras Shatarat et al.
Cardiomyopathy is a major cause of morbidity and mortality in Duchenne muscular dystrophy (DMD). Myocardial injury begins during a prolonged subclinical phase while left ventricular ejection fraction (LVEF) remains preserved, suggesting a p...
Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine [0.03%]
基于肠泌素的疗法、酒精和烟草使用以及急性物质相关事件：心血管医学领域的新兴影响
Ovidio De Filippo,Francesco Bruno,Federico Giacobbe et al.
Ovidio De Filippo et al.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual incretin agonists are now familiar drugs in obesity, diabetes, heart failure, and cardiovascular prevention. At the same time, a clinically relevant but molecule-specific human l...
Jacopo D&#x;Andria Ursoleo,Giuseppe Biondi-Zoccai,George W Booz
Jacopo D&#x;Andria Ursoleo
Clopidogrel resistance in ischemic stroke patients: current insights, risk factors, and the role of platelet function testing - a narrative review [0.03%]
缺血性卒中患者氯吡格雷抵抗的现状、危险因素及血小板功能检测的作用：叙事综述
Weihua Li,Yan Zhao,Mengchen Yu et al.
Weihua Li et al.
Clopidogrel, as an antiplatelet drug, is important for the treatment of the secondary prevention of ischemic stroke according to the latest guidelines on ischemic stroke management. However, some patients still fail to achieve a drug respon...
Pharmacologic Management of Type 2 Myocardial Infarction: An Underdefined Frontier [0.03%]
二型心肌梗死的药理学管理：一个尚不明确的领域
Chanokporn Puchongmart,Cristian Castillo Rodriguez,Dina Soliman et al.
Chanokporn Puchongmart et al.
Type 2 myocardial infarction (T2MI) results from myocardial oxygen supply-demand imbalance in the absence of acute atherothrombotic plaque rupture and is associated with substantial short- and long-term mortality. Although increasingly reco...
INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA [0.03%]
射血分数降低的心力衰竭患者使用阿那白滞素治疗后IL-1受体拮抗剂水平变化
Jazmin Kelly,Eleonora Mezzaroma,Andrea Roscioni et al.
Jazmin Kelly et al.
Patients with heart failure and reduced ejection fraction (HFrEF) commonly show signs of systemic inflammation. Interleukin-1 (IL-1) is a pro-inflammatory cytokine, known to modulate cardiac function. We aimed to determine the effects of tr...
Albumin and Bleeding Risk in Hospitalized Patients Receiving Apixaban [0.03%]
阿哌沙班治疗患者的血浆白蛋白水平与出血风险的关系
Ashley E Woodruff,Shiqi Zhang,Bidoura Chowdhury et al.
Ashley E Woodruff et al.
Highly protein-bound anticoagulants such as warfarin and rivaroxaban have increased therapeutic effects in the setting of hypoalbuminemia due to increased free concentrations in the drug which result in increased bleed risk. Apixaban is als...
Reversal of the Anticoagulant Effect of Milvexian by 4-Factor PCC and rFVIIa in Healthy Participants: a Two-Part, Randomized, Crossover Study [0.03%]
健康参与者中特异性逆转Milvexian抗凝作用的四因子prothrombin复合物浓缩剂和重组活化因子Ⅶ的研究：一项两部分、随机、交叉对照研究
Victor Dishy,Sue Sha,Anastasiya Koshkina et al.
Victor Dishy et al.
Milvexian is a selective, oral factor XIa inhibitor. Individuals receiving anticoagulation may require prompt reversal of anticoagulative effects. This study assessed reversal of milvexian's anticoagulant effects by recombinant human factor...
Ceramide-phospholipid risk score associates with cardiovascular events and is lowered by atorvastatin, simvastatin and anti-PCSK9 treatments [0.03%]
鞘氨醇磷脂风险评分与心血管事件相关，并可通过阿托伐他汀、辛伐他汀和抗PCSK9药物治疗降低
Mika Hilvo,Angelika Witoslawska,Mitja Lääperi et al.
Mika Hilvo et al.
The aim of the study was to investigate the prognostic value of previously established ceramide-phospholipid risk score, CERT2, and its response to lipid-lowering treatments in patients with symptomatic or suspected coronary heart disease. ...